Acquired by PVH Corp (PVH) in 2010, Tommy Hilfiger accounted for 44% of the company’s total 4Q16 sales. The brand’s business rose 2.9% YoY.
PVH Corp owns the famous Tommy Hilfiger and Calvin Klein brands and recorded a 0.2% decline in its top line, which stood at $2.1 billion during 4Q16.
PVH Corp beat estimates in both earnings and revenues for 4Q16, marking the 11th-straight earnings beat, though its EPS fell 19% YoY to $1.23.
Analysts estimate EPS of ~$0.94 for 1Q17 and EPS of ~$0.95 for 2Q17.
The Gardasil franchise is Merck’s (MRK) leading vaccines franchise.
Merck’s (MRK) animal health segment operates in more than 140 countries worldwide.
Januvia and Janumet are two of Merck’s (MRK) blockbuster drugs in the diabetes franchise.
Remicade, one of the top-selling drugs for the treatment of inflammatory disorders, is losing its market share after the loss of exclusivity in European markets in 2015.
Merck (MRK) reported growth of 1% to $39.8 billion in its 2016 revenues as compared to $39.5 billion in 2015.
Merck (MRK) reported a 1% increase in its revenues to $39.8 billion in 2016.
Keytruda, a prescription medicine classified under Merck’s (MRK) immunooncology franchise, is used to treat non-small cell lung cancer as well as melanoma.
On a capital-structure-neutral basis, Merck currently trades at ~9.6x, which is much lower than the industry average of ~11.2x.
Novartis (NVS) has undergone various changes through acquisitions and divestitures over the last two years.
Novartis expects to absorb the impact of generic competition and expects its 2017 sales to be in line with its 2016 revenue at a constant exchange rate.
Alcon, Novartis’s (NVS) eyecare segment, is divided into two subsegments: surgical care and vision care.
Novartis’s Innovative Medicines segment, formerly referred to as its Pharmaceuticals segment, consists of products for therapeutic areas including oncology, respiratory, and established medicines.
Sandoz, the generics arm of Novartis (NVS), is the number two generic medicines provider worldwide, and it’s number one in differentiated generics.
On January 6, 2017, Novartis announced a collaborative agreement with Ionis Pharmaceutical (IONS) and its subsidiary, Akcea Therapeutics.
Novartis (NVS) reported no change in its revenue on a constant currency basis in 2016 compared to 2015. The company’s 2016 revenue fell to $48.5 billion.
Novartis’s valuation has followed the industry’s overall trend over the last five years. Whether the healthcare sector’s valuation rises or falls, Novartis will definitely be affected.